Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Elliott

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 10, 2002
Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injuryRossana Berti, Anthony J Williams, John R Moffett, et al.
Cell Metabolism|December 3, 2008
Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidationJérôme N Feige, Marie Lagouge, Carles Canto, et al.
Blood|March 15, 2003
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIPThomas J Sayers, Alan D Brooks, Crystal Y Koh, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Shock (Augusta, Ga.)|October 3, 2007
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemiaMartijn D de Kruif, Luclenne C Lemaire, Ida A Giebelen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2003
Systematic discovery of multicomponent therapeuticsAlexis A Borisy, Peter J Elliott, Nicole W Hurst, et al.
Cardiovascular Research|October 28, 2010
Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cellsAlexander Breitenstein, Sokrates Stein, Erik W Holy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2007
Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemiaMartijn D de Kruif, Lucienne C Lemaire, Ida A Giebelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 10, 2002
Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injuryRossana Berti, Anthony J Williams, John R Moffett, et al.
Cell Metabolism|December 3, 2008
Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidationJérôme N Feige, Marie Lagouge, Carles Canto, et al.
Blood|March 15, 2003
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIPThomas J Sayers, Alan D Brooks, Crystal Y Koh, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Shock (Augusta, Ga.)|October 3, 2007
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemiaMartijn D de Kruif, Luclenne C Lemaire, Ida A Giebelen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2003
Systematic discovery of multicomponent therapeuticsAlexis A Borisy, Peter J Elliott, Nicole W Hurst, et al.
Cardiovascular Research|October 28, 2010
Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cellsAlexander Breitenstein, Sokrates Stein, Erik W Holy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian, Steven Soignet, Don S Dizon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2007
Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemiaMartijn D de Kruif, Lucienne C Lemaire, Ida A Giebelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Pageof 3